CYP19A1 and breast carcinoma: They found that SLC1A5 was upregulated in endocrine therapy-resistant breast cancer cells, and inhibition of SLC1A5 suppressed the proliferation of breast cancer cells resistant to aromatase inhibitors (Chen et al., 2015).